Revolo Biotherapeutics Announces the Completion of Phase 1 Multiple Ascending Dose Clinical Trial of ‘1104
The positive safety profile supports dosing of ‘1104 at higher doses in upcoming Phase 2b trial in EoE NEW ORLEANS and CAMBRIDGE, UK, September 21, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced […]